A Study to Assess Etoricoxib Versus Diclofenac in Chinese Patients With Osteoarthritis of the Knee or Hip
Information source: Merck
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Osteoarthritis
Intervention: MK0663; etoricoxib / Duration of Treatment:4 Weeks (Drug); Comparator: diclofenac sodium tablet 75 mg / Duration of Treatment:4 Weeks (Drug)
Phase: Phase 4
Status: Active, not recruiting
Sponsored by: Merck Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Merck
Summary
A Study to Assess Etoricoxib versus Diclofenac in Chinese Patients with Osteoarthritis of the
Knee or Hip
Clinical Details
Official title: A Multicenter, Randomized, Parallel-Group, 4-Week, Double-Blind and Active Comparator-Controlled Study to Assess Efficacy, Safety, and Tolerability of Etoricoxib 60 Mg Once Daily Versus Diclofenac Sodium 75 Mg Twice Daily in the Treatment of Chinese Patients With Osteoarthritis of the Knee or Hip
Study design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: WOMAC pain subscale
Secondary outcome: WOMAC Physical function subscale; Womac Stiffness subscale; Patient Global Assessment of Response to Therapy; Investigator Global Assessment of Disease Status
Eligibility
Minimum age: 40 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Chinese males or females at least 40 years of age with osteoarthritis of the knee or
hip
Locations and Contacts
Merck Sharp & Dohme (China) Ltd., Beijing 100738, China
Additional Information
Starting date: December 2004
Last updated: September 7, 2006
|
